Rosetta Genomics Advances Development of its Body Fluids-Based Diagnostic Tests with Two New Collaborations
Product News Feb 02, 2011
Rosetta Genomics, Ltd., announces that it has signed two new agreements for the development and validation of microRNA-based diagnostics for various indications related to its Gen 3 products. The Company's Gen 3 tests will focus on cardiovascular indications, neurodegenerative diseases, women's health and early detection of certain cancers, and are designed to leverage microRNA biomarkers extracted from body fluids.
The agreements are with Tel Hashomer Medical Research Infrastructure and Services Ltd. and Carmel Medical Center, both based in Israel. These collaborations are an integral part of Rosetta Genomics' Gen 3 product development process as they leverage the capabilities and samples at specialized centers such as these to identify initial microRNA candidate biomarkers for the Company's discovery-stage projects.
"One of Rosetta Genomics' core strengths is our ability to rapidly advance high-value diagnostics through our development engine. Toward that end, we have made significant scientific and technological advances that allow us to optimize the extraction of microRNAs from various body fluids. We are using these capabilities to advance the development of our first body fluids-based tests, which are also our first line of tests outside of oncology," said Kenneth A. Berlin, President and CEO of Rosetta Genomics.
"Our goal is to obtain proof-of-concept data on at least one of our Gen 3 products this year," he continued.
"With encouraging preliminary data in two of these Gen 3 indications already, Rosetta will be conducting studies to determine if these results hold up over larger sample sizes. We remain very encouraged by the important role microRNAs can play in the future of diagnostics as they are informative in a wide range of pathological indications, allowing us the flexibility to focus on a multitude of disease areas, and develop high-value diagnostics addressing significant unmet medical needs. We look forward to entering into additional agreements relating to our Gen 3 products in the coming months."